Updates on Alexion Pharmaceuticals (NASDAQ: ALXN) ratings and price targets.
Alexion Pharmaceuticals (NASDAQ: ALXN) had its “Outperform” rating reiterated by Leerink Swann.
Piper Jaffray (NYSE: PJC) cut their price target on Alexion Pharmaceuticals to $83.00.
Barclays Capital (NYSE: BCS) initiated coverage on Alexion Pharmaceuticals. They placed an “Overweight” rating and a price target of $77.00 on the company.
Morgan Stanley (NYSE: MS) raised their price target on Alexion Pharmaceuticals to $67.00 on October 24th.
Alexion closed Thursday at $70.98, up $0.06, or 0.08 percent.
No comments:
Post a Comment